Search

everythinglearnresearchcommunity

for

Search:↓

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Erlotinib can cause nonscarring hair loss and itchy skin.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

A man developed skin issues from cancer medication, which improved with specific treatments.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Some drugs can cause skin, nail, and hair problems, which are important for healthcare professionals to recognize and report.

Chemotherapy often causes temporary hair loss, which is distressing and needs better treatment and support.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Stress hormone corticosterone blocks a growth factor to slow down hair stem cell activity and hair growth.

Cancer development is like natural selection, involving mutated cells and environmental factors.

Hair usually grows back 1-3 months after treatment for anagen effluvium, and children with Loose Anagen Hair Syndrome often improve by adolescence.

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Certain drugs that block specific enzymes can help treat prostate diseases.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Drug repurposing is a cost-effective way to find new uses for existing drugs, speeding up treatment development.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Dermoscopy is useful for diagnosing various skin, hair, and nail disorders and can reduce the need for biopsies.

New treatments targeting skin stem cells show promise for skin repair, anti-aging, and cancer therapy.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

Blocking IL-8 can reduce skin rashes from cancer treatment.